SG11201405552VA - Targeting aminoacid lipids - Google Patents
Targeting aminoacid lipidsInfo
- Publication number
- SG11201405552VA SG11201405552VA SG11201405552VA SG11201405552VA SG11201405552VA SG 11201405552V A SG11201405552V A SG 11201405552VA SG 11201405552V A SG11201405552V A SG 11201405552VA SG 11201405552V A SG11201405552V A SG 11201405552VA SG 11201405552V A SG11201405552V A SG 11201405552VA
- Authority
- SG
- Singapore
- Prior art keywords
- lipids
- targeting
- targeting aminoacid
- aminoacid lipids
- aminoacid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12001803 | 2012-03-16 | ||
PCT/EP2013/000698 WO2013135359A1 (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201405552VA true SG11201405552VA (en) | 2014-10-30 |
Family
ID=47901004
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201405552VA SG11201405552VA (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
SG10201610401XA SG10201610401XA (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201610401XA SG10201610401XA (en) | 2012-03-16 | 2013-03-11 | Targeting aminoacid lipids |
Country Status (21)
Country | Link |
---|---|
US (2) | US9878044B2 (en) |
EP (1) | EP2825156B1 (en) |
JP (2) | JP6527331B2 (en) |
KR (2) | KR20200036033A (en) |
CN (1) | CN104168888A (en) |
AU (2) | AU2013231638B2 (en) |
BR (1) | BR112014022451B1 (en) |
CA (1) | CA2867169C (en) |
DK (1) | DK2825156T3 (en) |
ES (1) | ES2644778T3 (en) |
HK (1) | HK1198924A1 (en) |
IL (1) | IL234550A (en) |
MX (1) | MX354811B (en) |
NO (1) | NO2825156T3 (en) |
NZ (1) | NZ631034A (en) |
PT (1) | PT2825156T (en) |
RU (1) | RU2654210C2 (en) |
SG (2) | SG11201405552VA (en) |
TW (1) | TWI586370B (en) |
WO (1) | WO2013135359A1 (en) |
ZA (1) | ZA201407490B (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2347775T3 (en) | 2005-12-13 | 2020-11-16 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CA2813466A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions |
CA2813751C (en) | 2010-10-06 | 2019-11-12 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CN110511939A (en) | 2011-10-03 | 2019-11-29 | 现代泰克斯公司 | Nucleosides, nucleotide and nucleic acid of modification and application thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
EP2833923A4 (en) | 2012-04-02 | 2016-02-24 | Moderna Therapeutics Inc | Modified polynucleotides for the production of proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
CA2870309C (en) | 2012-04-16 | 2024-02-20 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
PT2922554T (en) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Terminally modified rna |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
EP3981437A1 (en) | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
CN107708756A (en) | 2015-04-10 | 2018-02-16 | 哈佛学院院长等 | Immunocyte acquisition equipment and its preparation and application |
AR105910A1 (en) * | 2015-09-04 | 2017-11-22 | Obi Pharma Inc | GLICAN MATRICES AND METHOD OF USE |
PT3350157T (en) | 2015-09-17 | 2022-03-18 | Modernatx Inc | Compounds and compositions for intracellular delivery of therapeutic agents |
CN105505382B (en) * | 2015-12-04 | 2017-06-27 | 安徽师范大学 | A kind of preparation method and application of copper nano-cluster solution |
ES2924407T3 (en) | 2015-12-10 | 2022-10-06 | Modernatx Inc | Compositions and methods for the delivery of therapeutic agents |
ES2913626T3 (en) | 2015-12-22 | 2022-06-03 | Modernatx Inc | Compounds and compositions for the intracellular delivery of agents |
EP3411475A4 (en) | 2016-02-06 | 2019-09-11 | President and Fellows of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
TWI780045B (en) | 2016-03-29 | 2022-10-11 | 台灣浩鼎生技股份有限公司 | Antibodies, pharmaceutical compositions and methods |
KR20230110820A (en) | 2016-04-22 | 2023-07-25 | 오비아이 파머 인코퍼레이티드 | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
SG11201810256XA (en) | 2016-05-18 | 2018-12-28 | Modernatx Inc | Polynucleotides encoding relaxin |
CN115305229A (en) * | 2016-07-13 | 2022-11-08 | 哈佛学院院长等 | Antigen presenting cell mimetic scaffolds and methods of making and using same |
CA3032049C (en) | 2016-07-27 | 2023-11-07 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
WO2018035387A1 (en) * | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
EP3505628B1 (en) | 2016-08-24 | 2023-05-03 | Infusion Tech | Method for concentrating microorganism or extracting nucleic acid using dtbp |
WO2018038549A1 (en) * | 2016-08-24 | 2018-03-01 | 울산대학교 산학협력단 | Method for concentrating microorganism or extracting nucleic acid using dtbp |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP3541414A4 (en) | 2016-11-21 | 2020-11-11 | OBI Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
DE17829597T1 (en) * | 2016-11-30 | 2019-12-05 | Noxxon Pharma Ag | METHOD FOR THE POLYALKOXYLATION OF NUCLEIC ACIDS FOR THE RECOVERY AND RE-USE OF AN EXCESSIVE POLYALKOXYLATION REAGENT |
ES2940259T3 (en) | 2017-03-15 | 2023-05-04 | Modernatx Inc | Compound and compositions for intracellular delivery of therapeutic agents |
WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
MA49421A (en) | 2017-06-15 | 2020-04-22 | Modernatx Inc | RNA FORMULATIONS |
US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
CN111565706A (en) * | 2017-11-09 | 2020-08-21 | 免疫疫苗技术公司 | Pharmaceutical composition, process for the preparation of a particle size setting comprising lipid vesicles and use thereof |
WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
JP2022524537A (en) | 2019-03-13 | 2022-05-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Process for the preparation of lipid-added proteinaceous structures |
CN114728887A (en) | 2019-09-19 | 2022-07-08 | 摩登纳特斯有限公司 | Branched tail end lipid compounds and compositions for intracellular delivery of therapeutic agents |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2967069D1 (en) | 1978-01-16 | 1984-08-02 | Univ Boston | Effecting cellular uptake of molecules |
US4144034A (en) * | 1978-03-27 | 1979-03-13 | Texaco Inc. | Polyether-maleic anhydride reaction product containing motor fuel composition |
ATE31560T1 (en) | 1983-11-10 | 1988-01-15 | Hoesch Ag | METHOD AND DEVICE FOR ELECTROLYTIC DEPOSITION OF METALS. |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6030954A (en) | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
IT1254135B (en) | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | ACIL CARNITINE ESTERS WITH LONG CHAIN ALIPHATIC ALCOHOLS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, WITH ANTIBACTERIAL ACTIVITY. |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
DE69818987T2 (en) | 1997-05-21 | 2004-07-29 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford | COMPOSITION AND METHOD FOR DELAYING THE TRANSPORT BY BIOLOGICAL MEMBRANES |
EP1173600A2 (en) * | 1999-04-20 | 2002-01-23 | The University Of British Columbia | Cationic peg-lipids and methods of use |
AU7404800A (en) | 1999-09-30 | 2001-04-30 | Novo Nordisk A/S | A method for preparing conjugates between an antigen and mucosal binding component |
JP4678967B2 (en) * | 2001-03-08 | 2011-04-27 | 本田技研工業株式会社 | Gelling organic compound and gel using the same |
GB0106041D0 (en) * | 2001-03-12 | 2001-05-02 | Cancer Res Ventures Ltd | Lipids and liposomes |
EP3231445A1 (en) | 2001-05-18 | 2017-10-18 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
JP5093547B2 (en) * | 2001-08-24 | 2012-12-12 | 日本ケミカルリサーチ株式会社 | Zwitterionic lipids and their uses |
WO2003022910A1 (en) | 2001-09-08 | 2003-03-20 | Access Pharmaceuticals, Inc. | Synthesis and uses of polymer gel nanoparticle networks |
EP1308167A1 (en) | 2001-11-06 | 2003-05-07 | Pickl, Winfried, Ao. Univ. Prof. Dr. | Antigen presenting vesicles |
JP4331927B2 (en) * | 2002-08-29 | 2009-09-16 | 協立化学産業株式会社 | Inorganic nanoparticle-organic compound composite and one-dimensional array integrated structure thereof |
CA2536357A1 (en) * | 2003-05-29 | 2004-12-23 | The Scripps Research Institute | Targeted delivery to legumain-expressing cells |
DE602005025659D1 (en) | 2004-09-23 | 2011-02-10 | Guerbet Sa | |
US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
US20100104629A1 (en) | 2008-04-16 | 2010-04-29 | Abbott Laboratories | Cationic lipids and uses thereof |
US20090285881A1 (en) * | 2008-04-16 | 2009-11-19 | Abbott Laboratories | Cationic lipids and uses thereof |
WO2009129387A2 (en) * | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
RU2409587C2 (en) * | 2009-03-04 | 2011-01-20 | Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" | 1-hexadecyl-5-(1-pyrenebutyl)-n-(l-ornitile)-l-glutamate bischloride |
CN103179952B (en) | 2010-09-02 | 2015-06-03 | 斯克里普斯研究学院 | Nanoparticle-based tumor-targeted drug delivery |
US20120294924A1 (en) * | 2011-04-29 | 2012-11-22 | Thomas Tice | Peptide-Lipid Conjugates And Uses Thereof |
EP2825157B1 (en) * | 2012-03-16 | 2018-09-05 | Merck Patent GmbH | Aminoacid lipids |
-
2013
- 2013-03-11 SG SG11201405552VA patent/SG11201405552VA/en unknown
- 2013-03-11 ES ES13710293.5T patent/ES2644778T3/en active Active
- 2013-03-11 RU RU2014141545A patent/RU2654210C2/en active
- 2013-03-11 NZ NZ631034A patent/NZ631034A/en unknown
- 2013-03-11 EP EP13710293.5A patent/EP2825156B1/en active Active
- 2013-03-11 SG SG10201610401XA patent/SG10201610401XA/en unknown
- 2013-03-11 CA CA2867169A patent/CA2867169C/en active Active
- 2013-03-11 BR BR112014022451-0A patent/BR112014022451B1/en active IP Right Grant
- 2013-03-11 CN CN201380013774.1A patent/CN104168888A/en active Pending
- 2013-03-11 DK DK13710293.5T patent/DK2825156T3/en active
- 2013-03-11 JP JP2014561310A patent/JP6527331B2/en active Active
- 2013-03-11 MX MX2014010808A patent/MX354811B/en active IP Right Grant
- 2013-03-11 WO PCT/EP2013/000698 patent/WO2013135359A1/en active Application Filing
- 2013-03-11 US US14/384,702 patent/US9878044B2/en active Active
- 2013-03-11 AU AU2013231638A patent/AU2013231638B2/en active Active
- 2013-03-11 KR KR1020207008113A patent/KR20200036033A/en not_active Application Discontinuation
- 2013-03-11 KR KR1020147028906A patent/KR102208586B1/en active IP Right Grant
- 2013-03-11 NO NO13710293A patent/NO2825156T3/no unknown
- 2013-03-11 PT PT137102935T patent/PT2825156T/en unknown
- 2013-03-15 TW TW102109381A patent/TWI586370B/en active
-
2014
- 2014-09-09 IL IL234550A patent/IL234550A/en active IP Right Grant
- 2014-10-15 ZA ZA2014/07490A patent/ZA201407490B/en unknown
- 2014-12-11 HK HK14112479.9A patent/HK1198924A1/en unknown
-
2018
- 2018-01-11 US US15/867,985 patent/US11510988B2/en active Active
- 2018-01-12 AU AU2018200293A patent/AU2018200293B2/en active Active
- 2018-05-29 JP JP2018102256A patent/JP2018141015A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198924A1 (en) | Targeting aminoacid lipids | |
IL236563A (en) | Search-powered connection targeting | |
EP2903092A4 (en) | Connector | |
EP2830699A4 (en) | Aseptic connector | |
EP2916394A4 (en) | Connector | |
HK1199819A1 (en) | Aminoacid lipids | |
EP2902073A4 (en) | Connector | |
EP2810685A4 (en) | Connector | |
EP2903140A4 (en) | Generator | |
EP2891661A4 (en) | Mitochondrial targeting peptide | |
EP2833521A4 (en) | Stator | |
EP2902689A4 (en) | Connector | |
EP2902072A4 (en) | Connector | |
EP2911251A4 (en) | Connector | |
EP2871398A4 (en) | Connector | |
GB201215525D0 (en) | Elelectrical generator | |
EP2839756A4 (en) | Connector | |
EP2805385A4 (en) | Connector | |
EP2824376A4 (en) | Connector | |
GB2504497B (en) | Armour | |
EP2814560A4 (en) | Connector | |
EP2879246A4 (en) | Connector | |
SG2013014170A (en) | Targeted liposomes | |
EP2852007A4 (en) | Connector | |
PL2877809T3 (en) | Armour |